SCHEMBL22845335

SCHEMBL22845335

CNC(=O)c1ccc(-n2c(=O)c3c(n4ncc(Cc5ccc(OC)cc5)c24)CN(C(=O)c2ccc(Br)c(C#N)c2)CC3)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 3/20 0.36
MAPT P10636 4/20 0.35
HDAC6 Q9UBN7 3/20 0.35
POLB P06746 1/20 0.35
PRKAB2 O43741 1/20 0.34
PRKAG1 P54619 1/20 0.34
PRKAA2 P54646 1/20 0.34
PRKAA1 Q13131 1/20 0.34
PRKAG3 Q9UGI9 1/20 0.34
PRKAG2 Q9UGJ0 1/20 0.34
PRKAB1 Q9Y478 1/20 0.34
MEN1 O00255 2/20 0.34
ALDH1A1 P00352 2/20 0.34
KMT2A Q03164 2/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
HSD17B10 Q99714 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
TP53 P04637 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22845442 0.92 GRM5 (0.34) GRM5PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL22845502 0.92 GRM1 (0.34) GRM5HDAC6GRM1
SCHEMBL22845342 0.91 MAPK14 (0.35) GRM5MAPTHDAC6MEN1ALDH1A1
SCHEMBL22845448 0.91 MAPT (0.39) MAPTHDAC6POLBMEN1ALDH1A1
SCHEMBL22845444 0.87 MAPT (0.34) GRM5MAPTHDAC6POLBTP53
SCHEMBL22845232 0.86 GRM1 (0.34) GRM5MAPTHDAC6TP53GRM1
SCHEMBL22717403 0.86 AR (0.35) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL22845531 0.85 MAPK14 (0.35) GRM5
SCHEMBL22845478 0.84 LMNA (0.36) POLBPRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL22845334 0.84 GRM5 (0.32) GRM5ALDH1A1GRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820773-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2023-11-21 US disclosed
WO-2022115384-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2022-06-02 WO disclosed
US-20220000874-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2022-01-06 US disclosed
US-11136321-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2021-10-05 US disclosed
US-20200407361-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2020-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220000874-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL GRM5 3636/4885MAPT 651/4885HDAC6 12/4885
US-11136321-B2 Tricyclic compounds SLC10A1, PKD1, CEL GRM5 3636/4885MAPT 651/4885HDAC6 12/4885
US-11820773-B2 Tricyclic compounds SLC10A1, PKD1, CEL GRM5 3636/4885MAPT 651/4885HDAC6 12/4885
US-20200407361-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL GRM5 3636/4885MAPT 651/4885HDAC6 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.